NCT00995787 - Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions

Type II Diabetes Mellitus

Interventions

DRUG

AZD1656

Dose titration of oral suspension of AZD165 during 3 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 6 days

DRUG

Placebo

Dose titration of oral suspension of placebo during 3 days given twice daily. Subjects will thereafter be for another 6 days

Trial Locations (1)

Unknown

Research Site, San Diego